Apatinib and Adebrelimab in Combination With chemotherapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intrahepatic Cholangiocarcinoma (Icc)
Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Trial Timeline
Jan 22, 2025 → Oct 1, 2027
NCT ID
NCT06925516About Apatinib and Adebrelimab in Combination With chemotherapy
Apatinib and Adebrelimab in Combination With chemotherapy is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Intrahepatic Cholangiocarcinoma (Icc). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06925516. Target conditions include Intrahepatic Cholangiocarcinoma (Icc).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06925516 | Phase 2 | Recruiting |
Competing Products
20 competing products in Intrahepatic Cholangiocarcinoma (Icc)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Camrelizumab + Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + SNDX-6352 | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Pemigatinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| A4250 (odevixibat) | Ipsen | Phase 3 | 74 |
| Odevixibat | Ipsen | Pre-clinical | 20 |
| CGT4859 | Cogent Biosciences | Phase 1/2 | 38 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 3 | 74 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |
| Volixibat + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 3 | 74 |
| Maralixibat + Placebo | Mirum Pharmaceuticals | Phase 3 | 74 |
| HMPL-453 + Rabeprazole | HUTCHMED | Phase 1 | 28 |